Complejo Asistencial De Zamora Hospital Provincial De Zamora

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th	autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder	Recruiting	Phase 3	2026-06-17		NCT07655115

Clinical trials